PTGX Protagonist Therapeutics Inc
Price (delayed)
$38.35
Market cap
$2.35B
P/E Ratio
8.58
Dividend/share
N/A
EPS
$4.47
Enterprise value
$2.27B
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2
Highlights
The equity has soared by 101% YoY and by 27% from the previous quarter
The net income has surged by 61% since the previous quarter
The quick ratio has contracted by 25% YoY but it has grown by 17% from the previous quarter
Key stats
What are the main financial stats of PTGX
Market
Valuations
Earnings
Shares outstanding
61.38M
Market cap
$2.35B
Enterprise value
$2.27B
Price to earnings (P/E)
8.58
Price to book (P/B)
3.38
Price to sales (P/S)
5.43
EV/EBIT
8.12
EV/EBITDA
8.03
EV/Sales
5.22
Revenue
$434.43M
Gross profit
$434.43M
Operating income
$252.84M
Net income
$275.19M
EBIT
$279.41M
EBITDA
$282.3M
Free cash flow
$182.8M
Per share
Balance sheet
Liquidity
EPS
$4.47
EPS diluted
$4.23
Free cash flow per share
$2.97
Book value per share
$11.33
Revenue per share
$7.06
TBVPS
$12.1
Total assets
$744.73M
Total liabilities
$69.43M
Debt
$10.87M
Equity
$675.3M
Working capital
$544.24M
Debt to equity
0.02
Current ratio
12.48
Quick ratio
12.32
Net debt/EBITDA
-0.31
Margins
Efficiency
Dividend
EBITDA margin
65%
Gross margin
100%
Net margin
63.3%
Operating margin
58.2%
Return on assets
42.5%
Return on equity
47.7%
Return on invested capital
65.9%
Return on capital employed
40.1%
Return on sales
64.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTGX stock price
How has the Protagonist Therapeutics stock price performed over time
Intraday
-1.79%
1 week
2.02%
1 month
-1.36%
1 year
24.15%
YTD
-0.65%
QTD
-0.65%
Financial performance
How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$434.43M
Gross profit
$434.43M
Operating income
$252.84M
Net income
$275.19M
Gross margin
100%
Net margin
63.3%
The net margin has surged by 148% year-on-year and by 20% since the previous quarter
The operating margin has soared by 137% YoY and by 26% from the previous quarter
PTGX's operating income has surged by 70% since the previous quarter
The net income has surged by 61% since the previous quarter
Growth
What is Protagonist Therapeutics's growth rate over time
Valuation
What is Protagonist Therapeutics stock price valuation
P/E
8.58
P/B
3.38
P/S
5.43
EV/EBIT
8.12
EV/EBITDA
8.03
EV/Sales
5.22
Protagonist Therapeutics's EPS has surged by 55% QoQ
PTGX's P/E is 27% below its last 4 quarters average of 11.8
The equity has soared by 101% YoY and by 27% from the previous quarter
The P/B is 11% less than the last 4 quarters average of 3.8 and 9% less than the 5-year quarterly average of 3.7
The stock's price to sales (P/S) is 95% less than its 5-year quarterly average of 102.4 and 18% less than its last 4 quarters average of 6.6
Protagonist Therapeutics's revenue has increased by 34% QoQ
Efficiency
How efficient is Protagonist Therapeutics business performance
The ROIC has soared by 179% YoY and by 18% from the previous quarter
Protagonist Therapeutics's return on sales has surged by 149% YoY and by 20% QoQ
The company's return on equity rose by 37% QoQ
PTGX's ROA is up by 37% since the previous quarter
Dividends
What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTGX.
Financial health
How did Protagonist Therapeutics financials performed over time
Protagonist Therapeutics's total assets has soared by 108% YoY and by 23% from the previous quarter
The quick ratio has contracted by 25% YoY but it has grown by 17% from the previous quarter
The debt is 98% smaller than the equity
The equity has soared by 101% YoY and by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.